title: Pathogenesis of follicular lymphoma.
abstract: The hallmark t(14;18)(q32;q21) in follicular lymphoma (FL) results in constitutive overexpression of the BCL2 protein, allowing B cells to abrogate the default germinal center apoptotic program. Most tumors are characterized by recurrent secondary genetic alterations including genomic gains, losses, and mutations, some providing a growth advantage, including alterations in MLL2, EPHA7, TNFRSF14, and EZH2. The sequence in which these events occur and how they contribute to progression and ultimately to transformation is unclear. Lastly, crosstalk between neoplastic B cells and non-neoplastic immune and stromal cells in the microenvironment plays an important role in sustaining tumor cell growth, cultivating immune privilege, and promoting transformation.
authors.affiliation: Center for Lymphoid Cancer, BC Cancer Agency, Department of Pathology and Laboratory Medicine, and Division of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Robert
authors.initials: R
authors.lastname: Kridel
authors.forename: Laurie H
authors.initials: LH
authors.lastname: Sehn
authors.forename: Randy D
authors.initials: RD
authors.lastname: Gascoyne
mesh_terms: D017951:Antigen Presentation; D017209:Apoptosis; D001402:B-Lymphocytes / Q000473:pathology*; D002455:Cell Division; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D002869:Chromosome Aberrations; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics* / Q000648:ultrastructure; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics* / Q000648:ultrastructure; D018450:Disease Progression; D019254:Genes, bcl-2; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D008954:Models, Biological; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics* / Q000502:physiology; D014411:Neoplastic Stem Cells / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis / Q000235:genetics* / Q000502:physiology; D055153:Stem Cell Niche; D013601:T-Lymphocytes / Q000473:pathology; D014178:Translocation, Genetic; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2